Compare Consolidated Edison, Inc. (ED) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Consolidated Edison, Inc. trades at $110 (market cap $39.87B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Consolidated Edison, Inc. is far larger — about 41× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Consolidated Edison, Inc. pays a 3.26% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 76 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ED | MRVI | |
|---|---|---|
Market Cap | $39.87B | $972.90M |
Volume | 1,579,122 | 4,325,710 |
Sector | Utilities | Health |
52-Week High | $115.46 | $9.00 |
52-Week Low | $95.37 | $2.83 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $66.72B | $1.08B |
Dividend Yield | 3.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $109.60, up 2.24% with a bullish technical signal. The stock shows strong fundamentals with $16.92B revenue, 12.53% net margin, and consistent dividend payments. Recent earnings show mixed results with Q2 beat but Q1 miss. The company maintains solid cash flow generation of $4.8B from operations in 2025 while investing heavily in infrastructure.
ED presents a stable utility investment with moderate growth and reliable dividends, though analyst consensus leans heavily toward Hold (63%). Key risks include regulatory pressures and capital-intensive infrastructure demands. The current price sits above the $105.56 consensus target, suggesting limited near-term upside despite positive economic impact from New York operations.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
